Newsroom
Stay informed on our latest company updates, scientific advancements, clinical milestones, and corporate announcements as we continue advancing NLRP3-based medicines.
Rezera files for IPO to back NLRP3 work in peripheral artery disease
Endpoints News
Rebranded NodThera plans IPO to fund NLRP3 inhibitor’s push toward approval
FIERCE Biotech
Rezera Announces Positive RESOLVE-2 Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile for Ruvonoflast in Combination with Semaglutide
Targeting Residual Inflammation in Cardiovascular Disease
The Bio Report